BY CHRISTIAN BUNDGAARD
-
Lundbeck upgrades minimum expectations after another quarter of double-digit growth
Gross sales of Lundbeck’s strategic key merchandise elevated by over 20% within the third quarter.
-
Novo Nordisk completes DNA study with good results
The pharmaceutical business is currently evaluating the comprehensive information.
-
Ambu opens door to acquisitions after strategy shift
The Ambu chief executive officer is starting to wonder about whether Ambu must establish all its technology in-house, she informs MedWatch about the magazine of the medtech company…
-
Ambu CEO most concerned about tariffs and trade wars as US election is decided
The chief executive officer has actually not taken a setting on which governmental prospect would certainly be best for Ambu.
-
Leo Pharma’s crown jewel grows 70% in Q3 – CEO wants more
Nevertheless, a brand new treatment is ready within the wings and the CEO is eager to speak about it.
-
Novo Nordisk’s semaglutide shows “superior improvement” in patients with MASH – will submit to authorities in early 2025
Novo Nordisk intends to send an advertising and marketing application to both the FDA and EMA in the very first fifty percent of 2025.
-
Eli Lilly hires more Nordic employees as it ramps up presence in Novo’s backyard
” Component of our technique for the following number of years in the Nordics will certainly be finding out just how we end up being much more noticeable and involve even mor…
-
AGC Biologics appoints new chief executive
Moving forward, AGC will certainly be “your pleasant CDMO specialist.”
-
EU Parliament adopts new resolution: Urgent need to review medical device legislation
The resolution notes a number of things in the fairly brand-new MDR and IVDR regulations that require to be inspected.
-
EU Parliament adopts new resolution: Urgent need to review medical device legislation
The resolution lists several items in the relatively new MDR and IVDR rules that need to be scrutinized.
